EPHA2 and cancer: Notably, only 3% of 10,967 TCGA pan-cancer patients showed EphA2 mutations, with missense mutations, amplification, and deletion being the predominant EphA2 gene alterations [46], supporting the notion that the activity of EphA2 in cancer might predominantly rely on functional alterations of ligand/receptor interactions.